- Home
- FRPT vs RYTM Comparison
FRPT vs RYTM Comparison
Compare FRPT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPT
- RYTM
- Stock Information
- Founded
- FRPT 2004
- RYTM 2008
- Country
- FRPT United States
- RYTM United States
- Employees
- FRPT N/A
- RYTM N/A
- Industry
- FRPT Packaged Foods
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- FRPT Consumer Staples
- RYTM Health Care
- Exchange
- FRPT Nasdaq
- RYTM Nasdaq
- Market Cap
- FRPT 3.7B
- RYTM 3.8B
- IPO Year
- FRPT 2014
- RYTM 2017
- Fundamental
- Price
- FRPT $80.47
- RYTM $57.38
- Analyst Decision
- FRPT Strong Buy
- RYTM Strong Buy
- Analyst Count
- FRPT 16
- RYTM 12
- Target Price
- FRPT $138.73
- RYTM $75.42
- AVG Volume (30 Days)
- FRPT 1.2M
- RYTM 671.0K
- Earning Date
- FRPT 05-05-2025
- RYTM 05-07-2025
- Dividend Yield
- FRPT N/A
- RYTM N/A
- EPS Growth
- FRPT 54.83
- RYTM N/A
- EPS
- FRPT 0.31
- RYTM N/A
- Revenue
- FRPT $1,014,577,000.00
- RYTM $136,863,000.00
- Revenue This Year
- FRPT $23.05
- RYTM $43.84
- Revenue Next Year
- FRPT $21.58
- RYTM $65.62
- P/E Ratio
- FRPT $263.21
- RYTM N/A
- Revenue Growth
- FRPT 23.25
- RYTM 48.88
- 52 Week Low
- FRPT $71.19
- RYTM $35.17
- 52 Week High
- FRPT $164.07
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- FRPT 51.00
- RYTM 43.00
- Support Level
- FRPT $71.19
- RYTM $62.69
- Resistance Level
- FRPT $84.20
- RYTM $65.53
- Average True Range (ATR)
- FRPT 3.10
- RYTM 3.04
- MACD
- FRPT 1.62
- RYTM -0.73
- Stochastic Oscillator
- FRPT 71.34
- RYTM 1.14
About FRPT Freshpet Inc.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.